Related Experiment Video
Updated: Feb 2, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Coronary Artery Calcium and Cardiovascular Events in Patients With Familial Hypercholesterolemia Receiving Standard
Marcio H Miname1, Marcio Sommer Bittencourt2, Sérgio R Moraes1
1Heart Institute (InCor), University of São Paulo Medical School Hospital, São Paulo, Brazil.
Insights
Coronary artery calcium (CAC) scores effectively predict atherosclerotic cardiovascular disease (ASCVD) events in familial hypercholesterolemia (FH) patients on lipid-lowering therapy. Higher CAC scores indicate increased ASCVD risk, aiding in personalized treatment strategies.
Area of Science:
- Cardiology
- Preventive Medicine
- Medical Imaging
Background:
- Familial hypercholesterolemia (FH) significantly increases the risk of premature atherosclerotic cardiovascular disease (ASCVD).
- The clinical presentation of ASCVD in FH patients is variable, necessitating refined risk stratification tools.
- Coronary artery calcium (CAC) scoring is a valuable marker for subclinical atherosclerosis burden.
Purpose of the Study:
- To assess the predictive value of coronary artery calcium (CAC) for atherosclerotic cardiovascular disease (ASCVD) events.
- To evaluate CAC in asymptomatic primary prevention patients with molecularly proven heterozygous familial hypercholesterolemia (FH).
- To determine the role of CAC in patients already receiving standard lipid-lowering therapy.
Main Methods:
- Prospective follow-up of 206 FH subjects who underwent CAC measurement.
- Multivariate analysis was employed to evaluate the association between CAC and ASCVD events.
- Study included patients with a mean age of 45 years and high baseline LDL cholesterol levels.
Main Results:
- Coronary artery calcium (CAC) was detected in 51% of the study participants.
- A total of 15 ASCVD events (7.2%) occurred during a median follow-up of 3.7 years.
- Log(CAC score + 1) was independently associated with incident ASCVD events (HR: 3.33; p=0.001), with event rates increasing significantly with higher CAC scores.
Conclusions:
- Coronary artery calcium (CAC) is an independent predictor of ASCVD events in familial hypercholesterolemia (FH) patients on lipid-lowering therapy.
- CAC scoring can enhance risk stratification for FH patients, identifying those who may benefit from intensified treatment.
- This study supports the use of CAC to refine risk assessment in primary prevention for FH individuals.
Objectives:
The aim of this study was to evaluate the role of coronary artery calcium (CAC) as a predictor of atherosclerotic cardiovascular disease (ASCVD) (fatal or not myocardial infarction, stroke, unstable angina requiring revascularization, and elective myocardial revascularization) events in asymptomatic primary prevention molecularly proven heterozygous familial hypercholesterolemia (FH) subjects receiving standard lipid-lowering therapy.
Background:
FH is associated with premature ASCVD. However, the clinical course of ASCVD in subjects with FH is heterogeneous. CAC score, a marker of subclinical atherosclerosis burden, may optimize ASCVD risk stratification in FH.
Methods:
Subjects with FH underwent CAC measurement and were followed prospectively. The association of CAC with ASCVD was evaluated using multivariate analysis.
Results:
A total of 206 subjects (mean age 45 ± 14 years, 36.4% men, baseline and on-treatment low-density lipoprotein cholesterol 269 ± 70 mg/dl and 150 ± 56 mg/dl, respectively) were followed for a median of 3.7 years (interquartile range: 2.7 to 6.8 years). CAC was present in 105 (51%), and 15 ASCVD events (7.2%) were documented. Almost one-half of events were hard outcomes, and the others were elective myocardial revascularizations. The annualized rates of events per 1,000 patients for CAC scores of 0 (n = 101 [49%]), 1 to 100 (n = 62 [30%]) and >100 (n = 43 [21%]) were, respectively, 0, 26.4 (95% confidence interval: 12.9 to 51.8), and 44.1 (95% confidence interval, 26.0 to 104.1). In multivariate Cox regression analysis, log(CAC score + 1) was independently associated with incident ASCVD events (hazard ratio: 3.33; 95% CI: 1.635 to 6.790; p = 0.001).
Conclusions:
CAC was independently associated with ASCVD events in patients with FH receiving standard lipid-lowering therapy. This may help further stratify near-term risk in patients who might be candidates for further treatment with newer therapies.
Related Concept Videos
Family Therapy
Strategic Family Therapy
Strategic family therapy emphasizes resolving communication barriers and improving problem-solving abilities...
Gene Families
Occasionally these regions can be adapted to take on new roles within the organism, becoming novel genes...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Coronary Artery Disease I: Introduction
Protein Families
Coronary Artery Disease II: Pathophysiology

